Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors

https://doi.org/10.1016/0002-9149(93)90858-AGet rights and content

Abstract

This placebo controlled, multinational study evaluated the use of pravastatin in 1,062 patients with hypercholesterolemia (serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter [200 to 300 mg/dl]) and ⪰2 additional risk factors for atherosclerotic coronary artery disease. Efficacy and safety analyses were performed on the initial 26-week, randomized, double-blind, placebo-controlled period; further safety analyses were conducted on the subsequent 52 weeks, which included an additional 26-week double-blind phase permitting other lipid-lowering agents and a final 26-week open-label period. At 13 weeks, pravastatin at a dose of 20 ing once daily at bedtime significantly lowered serum low-density lipoprotein cholesterol 26% (4.7 to 3.5 mmol/liter [182 to 135 mg/dl]), total cholesterol 19% (6.8 to 5.6 mmol/liter [263 to 217 mg/dl]) and triglycerides 12% (1.8 to 1.6 mmol/liter [159 to 142 mg/di]) (p <0.001 compared with placebo) and significantly raised serum high-density lipoprotein cholesterol 7% (1.1 to 1.2 mmol/liter [43 to 46 mg/dl]) (p <0.001 compared with placebo). Efficacy of pravastatin was maintained at 26 weeks, and during this initial period there were significantly more serious cardiovascular adverse events in the placebo group (13 events, 2.4%) than in the pravastatin group (1 event, 0.2%) (p <0.001). Six myocardial infarctions, 5 cases of unstable angina and 1 sudden cardiac death occurred in the placebo group, compared with none of these events in the pravastatin group. In this study, pravastatin produced beneficial effects on serum lipids and was associated with a reduction in the incidence of serious cardiovascular adverse events.

References (25)

  • W.B. Kannel et al.

    Serum cholesterol, lipoproteins, and the risk of coronary heart disease: the Framingham Study

    Ann Intern Med

    (1971)
  • The Lipid Research Clinics Program

    The Lipid Research Clinics Coronary Primary Prevention Trial results, I: reduction in incidence of coronary heart disease

    JAMA

    (1984)
  • Cited by (238)

    • Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance

      2013, Atherosclerosis
      Citation Excerpt :

      Thus, the original STOMP report [2] and the present data demonstrate that high-dose statin treatment does not detrimentally impact muscular performance, even in those individuals displaying exaggerated CK responses. Most prior clinical trials defined statin-associated myopathy as CK levels > than 10 times the ULN [3–9]. No subject in STOMP persistently demonstrated such a large CK response.

    View all citing articles on Scopus

    This study was supported by a grant from Bristol-Myers Squibb Company, Princeton, New Jersey.

    See Appendix for the list of participants.

    View full text